Insmed Announces Second Quarter and First Half Earnings Release Date and Conference Call
25 Juillet 2007 - 3:15PM
Business Wire
Insmed Inc. (Nasdaq:INSM) today announced that it will release its
2007 second quarter and first half results before the market opens
on Thursday, August 2, 2007. Management will host an investment
community conference call beginning at 11:00 a.m. (ET) to discuss
the financial results, provide a business update and answer
questions. Individuals interested in listening to the live
conference call may do so by dialing 877-407-0782 toll free within
the U.S. and Canada, or 201-689-8567 for international callers. A
telephone replay will be available approximately two hours after
the call for two weeks by dialing 877-660-6853 from the U.S., or
201-612-7415 for international callers. The account # is 286 and
conference id # 249996. Individuals interested in listening to the
conference call via the Internet may do so by visiting
www.insmed.com. A replay will be available on the Company's Web
site for 90 days. About Insmed Incorporated Insmed is a
biopharmaceutical company focused on the development of drug
candidates for the treatment of metabolic diseases and endocrine
disorders with unmet medical needs. For more information, please
visit www.insmed.com. Forward Looking Statements This release
contains forward-looking statements which are made pursuant to
provisions of Section 21E of the Securities Exchange Act of 1934.
Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design,
regulatory and business strategies, plans and objectives of
management and growth opportunities for existing or proposed
products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ
materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, the Company may
lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies
differently than the Company, competing products may be more
successful, demand for new pharmaceutical products may decrease,
the biopharmaceutical industry may experience negative market
trends and other risks and challenges detailed in the Company's
filings with the U.S. Securities and Exchange Commission, including
the Company�s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. Readers are cautioned not to place undue reliance
on any forward-looking statements which speak only as of the date
of this release. The Company undertakes no obligation to publicly
release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that
occur after the date of this release or to reflect the occurrence
of unanticipated events.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024